Status:
COMPLETED
Contribution of SuPAR for Patients in a Situation of Uncertainty Downstream of Emergencies
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Emergencies
Disease
Eligibility:
All Genders
18+ years
Brief Summary
In this study, the investigators will investigate the relationship between the blood level of SuPAR at admission to the emergency department of the Clermont-Ferrand University Hospital, and the outcom...
Detailed Description
SuPAR (Soluble urokinase Plasminogen Activator Receptor) is a non-specific prognostic blood biomarker related to inflammation. An elevated SuPAR value reflects significant chronic inflammation and pre...
Eligibility Criteria
Inclusion
- Patient, male or female, over 18 years old
- Admitted to the emergency department of the Clermont-Ferrand University Hospital for a medical reason,
- Classified as FRENCH II or III by the nurse organizer of the reception management
- Necessity of clinical observation in the Short Term Hospitalization Unit for final orientation decision
- Requires a blood test upon arrival in the emergency department
- Able to give informed non-opposition to participate in the research.
- Affiliation to a Social Security system
Exclusion
- Patient under guardianship or curatorship
- Pregnant and breast feeding woman
- Patient admitted for psychiatric pathology
- Patient with a limitation of therapeutics
- Refusal to participate
- Patient hospitalized because of a particular social context
Key Trial Info
Start Date :
January 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 18 2022
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT05214534
Start Date
January 10 2022
End Date
April 18 2022
Last Update
March 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU clermont-ferrand
Clermont-Ferrand, France